MolecularMD engages in the clinical development and commercialization of genomic assays/pharmacogenomic tests to measure patient molecular response and resistance to targeted cancer therapies in Oregon. The company focuses on providing clinical trial services. It offers laboratory services, such as laboratory certification, test capacity from phase I trials to phase III/IV international trials, and data management; and support services comprising assay development, field and trial site support, and physician education.